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Effects of antihypertensive treatment in one—clip, two kidney hyperten-
sion in rats. In order to investigate the consequences of
antihypertensive therapy on hormonal and renal parameters in
one—clip, two kidney renovascular hypertension, we compared the
effects of converting enzyme inhibition (CEI) with those of
tripletherapy (clonidine, dihydralazine and furosemide) in this experi-
mental model in rats. The treatment period was initiated four weeks
after application of the clip and was continued for five weeks. In
plasma, renin was increased and renin substrate was negatively corre-
lated to plasma renin. Hypertension was associated with activation of
the renin angiotensin system in both plasma and kidney. The degree of
activation of the renin—angiotensin system in the clipped kidney and its
suppression in the unclipped kidney was evaluated by two methods,
renal renin content and semi-quantification of juxtaglomerular
hyperplasia by immunofluorescent renin. These two methods were
correlated, During the treatment period, average systolic blood pres-
sure was 144 13 mmHg in the CEI treated group (HT1) which was not
significantly different from the value found in the sham—operated group
(139 4 mmHg; C2). Blood pressure, however, was lowered only to
173 18 mmHg in the group treated with tripletherapy (HT2). In
control hypertensive animals, the wt of the clipped kidney did not
decrease whereas significant hypertrophy was present in the unclipped
kidney. Tripletherapy did not alter this relationship, whereas convert-
ing enzyme inhibition decreased kidney wt in the clipped kidney and
increased further the hypertrophy of the contralateral unclipped kidney.
A histological examination revealed that hypertensive microangiopathy
was a predominant feature in the unclipped kidney of the untreated
hypertensive group and of the group treated with tripletherapy, these
lesions were completely absent in the CEI treated group. In the CEI
treated group, however, ischemic lesions during this treatment were
found to be decreased in the contralateral unclipped kidney and
increased in the clipped kidney by comparison with untreated hyper-
tensive rats. These renal lesions observed in the clipped kidney were
most likely related to the normalization of blood pressure or to a
disturbance of intrarenal mechanisms normally mediated by the
renin—angiotensin system during stenosis of a renal artery.
Although both short and long term regulation of the
renin—angiotensin system in plasma and in the kidney as well as
morphological changes in the kidney have been described in
experimental renovascular hypertension [1—31, the effects of
antihypertensive therapy on these parameters have not been
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extensively evaluated. Recently, several authors have reported
in human renovascular hypertension, deleterious effects on
renal function associated with the use of potent antihyperten-
sive drugs [4, 5], especially converting enzyme inhibitors when
stenosis of the renal artery is present bilaterally or in a solitary
kidney [6—151. When the renal artery stenosis is unilateral and
the contralateral kidney is not affected by the renovascular
disease, serum creatinine level cannot be used as a marker of
the effect of antihypertensive drugs on the stenotic kidney.
Only three reports in man have evaluated the effects of
antihypertensive therapy on the stenotic kidney when the
contralateral kidney was not affected. Dean et al [16] reported
that chronic antihypertensive treatment which did not include
converting enzyme inhibitors were associated with a decrease
in size as well as function of the stenotic kidney. Wenting et al
[17] reported that both glomerular filtration rate as well as renal
plasma flow decreased in the affected kidney in response to
converting enzyme inhibition. Hodsman et al [181 have also
shown with enalapril therapy that renal plasma flow increased
in the unaffected kidney and decreased even further in the
stenotic kidney. Observations made by Bengis and Coleman
[19] and Helmchen et al [20] suggest that these phenomenons
are also observed in experimental renovascular hypertension in
rats.
For these reasons, we undertook studies to evaluate the
effects of chronic antihypertensive therapy and particularly of
converting enzyme inhibition in an experimental model of
one—clip, two kidney hypertension in rats. We describe here the
hemodynamic, hormonal and renal morphological conse-
quences of two antihypertensive regimens, either tripletherapy,
consisting of dihydralazine, clonidine and a diuretic, or treat-
ment with a single agent, namely, a converting enzyme inhibitor
[21]. Besides renin measurements in plasma and kidney, quan-
tification ofjuxtaglomerular hyperplasia was made by the use of
a renin—immunofluorescent index and renin substrate was mea-
sured. All these indexes were used to quantify the level of
activation of the renin angiotensin system during the time
course of experimental hypertension and under the influence of
treatment. Histological lesions differed in the stenotic and
contralateral kidney of treated and untreated rats, and were
related to the type of treatment and to the level of blood
pressure.
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Methods
Six—week—old male white Wistar rats weighing 133 10 g
were used throughout this study.
Operative procedures
A total of 125 rats were operated under ether anesthesia. In
105 rats, the right renal artery was clipped (0.2 mm diameter),
and the left kidney was not disturbed. Twenty rats were
sham-operated.
The animals were returned to their cages, and fed a standard
rat diet. Water was provided ad libiturn. From the first to the
fourth week after application of the clip, systolic blood pressure
was measured once a week, at the same time of the day, using
a tail cuff method. Body wt was measured twice weekly.
Fifty eight rats were eliminated from the study because they
either failed to develop hypertension (that is, systolic blood
pressure less than 150 mm Hg, N = 19), they developed
malignant hypertension marked by rapid loss of wt (N 27) or
they died (N = 12).
Hypertensive rats were randomized into four groups, four
weeks after application of the clip. The first group (HC1
hypertensive controls, N Ii) was sacrificed by rapid decap-
itation on the same day as a control group of sham-operated
rats (Cl controls, N = 6). The study was pursued for nine
weeks after application of the clip in the other three groups. The
control group (HC2, N 12) received no treatment throughout
the course of the study. At the beginning of the fifth week,
treatment was initiated as follows in the remaining groups and
continued until the termination of the study. The third group
(HT2, N = 12) was treated with tripletherapy, that is: clonidine,
0.1 mg/kg; dihydralazine, 7.5 mg/kg; each subcutaneously,
twice daily; and furosemide, 30 mg/kg/day, administered in the
drinking water. Each day, the amount of furosemide ingested
was determinated by measurement of the water intake from the
previous day. The fourth group (HT1, N = 12) was treated with
a converting enzyme inhibitor (CE!, S9490) [21] using a single
oral daily dose of 0.5 mg/kg, During this second period of five
weeks, the measurements of BP and body wt were carried out
in a manner identical to the first period.
Nine weeks after clipping, the three groups of renovascular
hypertensive rats were sacrificed by decapitation, together with
a group of sham-operated rats (group C2, N 13).
Blood samples were collected from the unanesthetized rats at
the time of decapitation. The first 2 mliters of blood were
collected in tubes containing 50 .diter of 200 JiM EDTA (pH 6.5)
and the remaining blood was collected in heparinized tubes.
The blood samples were centrifuged for 15 mm at 3.000xg and
the plasma was removed and frozen at —30°.
Plasma measuretnent
Plasma renin concentration. Renin concentration of plasma
collected during decapitation was measured by radio-
immunoassay (RIA) of angiotensin I generated by incubation
with an excess of rat renin substrate [22].
Plasma renin substrate activity. Angiotensin was measured
by incubation of the plasma with an excess of mouse subrnaxil-
lary gland renin (20 x iO— Goldblatt Units) and the angioten-
sin I liberated was measured by RIA as described previously
[22].
Direct RIA of plasma renin substrate. Measurement of total
plasma angiotensinogen was done by direct radioimmunoassay
according to the method of Bouhnik et al [23]. This method
measures the parent compound angiotensinogen, as well as its
metabolite, des-angiotensin 1-angiotensinogen. Comparison of
the results of the direct assay with those of the indirect assay,
which measures only the parent compound, indicates the quan-
tity of des-angiotensin 1-angiotensinogen in the circulating
plasma 124].
Plasma aldosterone. Plasma aldosterone was measured by
the RIA method of Pham and Corvol [25].
Plasma converting enzyme. Angiotensin I converting enzyme
activity was quantified using 3M Benzol-glycyl-glycyl-glycine
according to the method of Ryan et al [26] with minor modifi-
cations [27].
Plasma creatinine. Plasma creatinine level was measured by
the method of Jaffe (Kit Roche "diagnostic" Ref 1421).
Plasma volume. Plasma volume was calculated from the
volume of distribution of l131 human albumin, ten minutes after
the i.v. injection of 0.4 JiCi.
Measurement of renal renin content
One-halfof each kidney was frozen. After thawing, renin was
extracted as previously described [28]. Tissue renin activity
was measured by the radloimmunoassay of angiotensin I.
Protein measurement was made according to the method of
Lowry.
Immunofluorescent renal ream index. Pure mouse submaxil-
lary gland renin was prepared according to Cohen et al [29].
Homogeneity of the enzyme was demonstrated by the presence
of a single band on S.D.S. polyacrylamide gel electrophoresis,
and of a single NH2-terminal amino acid as shown by dansyla-
tion experiments. Antisera were raised in rabbits. Immunodif-
fusion and immunoelectrophoresis showed a single precipita-
tion line with submaxillary renin [30]. These antibodies are able
to bind 50% of iodinated pure mouse renin, at a dilution of
1:30,000 to 1:100,000 and to inhibit the enzymatic activity of
mouse plasma renin at a dilution of 1:3,000 to 1:10,000.
Entire kidney specimens were fixed in Dubosq Brazil solution
and embedded in paraffin. Three micron thick sections of all
sagittal surfaces of the kidney were deparafinized in xylene (for
5 mm), passed through decreasing concentrations of ethanol,
and washed in phosphate buffered saline. Indirect immunoflu-
orescence was carried out as follows: sections were exposed to
unlabeled rabbit antisubmaxillary mouse renin antiserum at a
1:50 dilution for 30 mm. After washing, tissue sections were
incubated with fluoresceinated goat antirabbit immunoglobulin
(Hyland Laboratoires, Costa Mesa, California, USA). The
slides were mounted in buffered gelatin and examined under
ultraviolet light with a Leitz Ortophan Ortemat microscope
(Fig. I). In control kidney tissue sections, antirenin antiserum
was omitted or replaced by rabbit preimmun serum.
To quantify the renin content of each kidney by im-
munofluorescence, we calculated the ratio of the number of
immunofluorescent juxtaglomerular apparatus (JGA) and af-
ferent (AA) and interlobular arterioles (ILA) to the total number
of glomeruli present in the section of the kidney.
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120 40%) remained less than the body wt of sham—operated
rats (+ 144 17%, P < 0.05). The changes in body wt of CE!
treated rats (HT1 rats, + 121 19%) did not differ from the
untreated hypertensive rats. In those animals treated with
tripletherapy (HT2), growth was less than the growth of either
the HC2 or the HT1 groups (+ 97 18%, P < 0.05) (Tables I
and 2).
Blood pressure (BP)
Fig. 1. Section of ischemic kidney stained with anhirenin antiserum
diluted 1/50. Positive reactions are seen in the vascular pole of
glomeruli and in the wall of interlobular arteries (X 168).
Immunofluorescent renal renin index =
number of fluorescent JGA, AA, and ILA
total number of glomeruli
An average of 250 glomeruli was counted per section. 134
kidneys were read in this manner.
Light microscopy
Entire kidney specimens were fixed in Dubosq Brazil solu-
tion, embedded in paraffin and cut into two micron sections.
The sections were stained with hematoxylin-eosin-saffran, Mas-
son's trichrome with light green and silver impregnation as
described by Marinozzi.
Statistical methods
Results are expressed as means SD. Paired t tests were
used to compare measurements made in the same animals. The
Wilcoxon's test was used to compare results between plasma
values. Correlation coefficients were obtained by the least
squares method. The exact test of Ficher was used for compar-
ison of the frequency of histological lesions in the different
groups, Proportional replicated two way analysis of variance
and simultaneous multiple comparison procedures (Bonferroni
method) were used for mean comparison of one parameter
under different experimental conditions. Analysis of covariance
was performed to test the influence of the various experimental
conditions on the relationship between renal indices in the
clipped and the contralateral kidney [311.
Results
Body weight
The body wt of the clipped rats and of the sham-operated rats
were identical at the beginning of the study (132 9 g vs. 134
11 g). Following application of the clip, the increase in body wt
of clipped rats was less than that of the sham—operated rats and,
by the end of the fourth week, the increase in body wt was
significantly greater in the sham—operated group (+ 75 12%)
than in the hypertensive group (+ 49 25%) (P <0.001). At the
ninth week the increase in body wt in untreated rats (HC2, +
Four weeks after clipping one renal artery the systolic BP of
hypertensive rats was 239 32 (N = 48) vs. 134 8 mm Hg(N = 19) in the sham—operated controls. The BP of HC1 rats
sacrificed at the fourth week was 243 34 mm Hg (N = 11).
During the next four weeks, no treated animals developed
malignant hypertension, whereas two untreated animals died
during this treatment period and were eliminated from the
study. The average systolic BP of the HC2 hypertensive control
group from the fifth to the ninth week was 215 32 mm Hg vs.
139 4 mm Hg in the sham-operated rats. Treatment with CE!
dramatically reduced BP as soon as the fifth week BP remained
low during the final four weeks of the experiment (average BP:
144 13 mm Hg), and was not significantly different from the
sham-operated group. Antihypertensive tripletherapy was not
as effective as converting enzyme inhibition in lowering BP.
Although blood pressure was reduced by tripletherapy, it did
not return to control values. The average BP (from the 5th to
the 9th week) in the C2 and HT1 groups was 139 4 mm Hg and
144 13 mm Hg respectively, whereas BP remained more
elevated (173 18 mm Hg) in the tripletherapy treated group
(HT2).
Plasma renin—angiotensin system
In the sham-operated group, all components of the plasma
renin—angiotensin system (PRC, direct and indirect plasma
renin substrate and aldosterone) did not change significantly
between the fourth and the ninth week, except converting
enzyme activity which increased significantly (P < 0.01). In
contrast, in the untreated hypertensive groups activation of the
renin—angiotensin system was greater at four weeks than at nine
weeks. Plasma renin concentration as well as plasma aldoster-
one were higher at four weeks (HC1) than at nine weeks (HC2)
(P <0.001), even if the level of renin and of aldosterone at nine
weeks remained higher that the values of the same parameters
in the sham-operated group (P < 0.001). There were no statis-
tically significant differences in renin substrate determined by
direct assay. The values resulting from the indirect assay of
renin substrate have no significant tendencies to decrease (F =
4.01, P = 0.052) in both groups of untreated hypertensive
animals as compared to sham-operated group. Plasma volume
was significantly increased in hypertensive rats at the 9th week
(36 13 vs. 32 2 mliter/kg, P < 0.05).
Tripletherapy (HT2) increased plasma renin concentration
compared to the untreated hypertensive animals. In parallel,
there were no changes in renin substrate determined by the
direct assay, whereas those values obtained by the indirect
assay of angiotensinogen decreased. There were no changes in
converting enzyme activity and in plasma aldosterone in this
group (HT2) compared to HC2. Plasma volume was higher than
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Table 1. Plasma and renal parameters of the renin—angiotensin system in sham—operated and untreated hypertensive animals
Controls Renovascular hypertension
Systolic BP, mmHg
Body wt, g
Immunofluorescent renal renin index, %
Right kidney
Left kidney
Renal renin content, g A,/mg prot/hr
Right kidney
Left kidney
Plasma renin concentration
ng A1/ml/hr
Direct angiotensinogen concentration
pmoie/ml
Renin substrate activity
pmo!e A,/ml
Converting enzyme activity
mU/mi
Plasma aldosterone
ng/100 ml
4 weeks 9 weeks 4 weeks 9 weeks
C, N = 6 C2, N = 13 (HC1, N = II) (HC,, N = 12)
43.1 15.9
14.8 8.9
13.7 9.8
2.06 1.9
43 36
690 136
657 208
63 20
81 33
Table 2. Plasma and renal parameters of the renin—angiotensin system in animals sacrificed at nine weeks
Sham-operated
C2, N = 13
Untreated
hypertension
HC2, N = 12
Triple therapy
HT2, N = 12
Converting enzyme
inhibition
HT1, N = 13
Mean systolic BP, 5th—9th weeks, mm Hg 139 4 215 32 173 18 144 13
Body wt, g 321 34 304 55 258 26 282 23
Immunofluorescent renal renin index, %
Right clipped kidney 24.0 6.3 43.1 15.9 55.2 9.7 98.1 21.2
Left unclipped kidney 25.3 6.0 14.8 8.9 6.9 3.8 26.8 12.4
Renal renin content, ,g A,/mg proi/hr
Right clipped kidney 4.7 1.1 13.7 9.8 24.3 14.5 54.5 32
Left unclipped kidney 5,3 2.3 2.06 1.9 0.9 0.3 5.1 3.7
Plasma renin concentration,
ngA,/mi/h 20 7 43 36 104 89 146 81
Direct angiotensinogen concentration,
pmole ml 736 175 690 136 657 176 723 145
Renin substrate activity,
pmoleA,/mi 731 125 657 208 504 157 386 151
Converting enzyme activity,
mU/mi 87 12 63 20 86 23 26 13
Plasma aldosterone,
ng/lOOml 45 27 81 33 81 66 50 30
Plasma volume,
mi/kg 32 2 36 13 40 9 35 4
in untreated hypertensive rats (40 9 vs. 36 13 muter/kg, P
<0.05).
In contrast, in the group treated with converting enzyme
inhibition (HT1), converting enzyme activity and plasma aldos-
terone concentrations decreased significantly. Plasma volume
was identical to that of hypertensive untreated rats but still
higher than in control rats (P < 0.02). Plasma renin concentra-
tion increased significantly (P < 0.001) and renin substrate
determined by indirect assay was significantly decreased,
whereas those values obtained by direct assay of renin sub-
strate did not change (Table 2).
In the different groups sacrificed at nine weeks (C2, HC2,
HT,, HT1) there was a general intergroup negative correlation
between the increase in plasma renin concentration and the
decrease in plasma renin substrate activity (r =
—0.49, F =
15.3, P < 0.001) (Fig. 2).
Kidney weight
The absolute value for kidney wt increased between four and
nine weeks in the sham-operated groups (Left kidney wt,
(L.K.W.) C1: 770 SI mg, C,: 897 123 mg; right kidney wt,
(R.K.W.) C1: 794 48 mg, C,: 888 84mg). The kidney wt to
body wt ratio significantly decreased between four and nine
weeks (L.K.W./B.W., C1 3.21 0.25, C2 2.80 0.27;
R.K.W./BW: C1 3.31 0.26; C2 2.78 0.21 mglg, F = 29.8, P
<0.001).
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Fig. 2. Histograms of direct () and indirect (Z) plasma renin
substrate measurement and plasma renin concentration in the four
groups of animals sacrificed at nine weeks. The increasing amount of
peripheral consumption of angiotensinogen was related to the increas-
ing level of plasma renin concentration.
In the untreated hypertensive group sacrificed at four weeks,
the absolute wt of the right clipped kidney was significantly
lower than in the sham-operated group (R.K.W. HC1: 686
100 mg, P < 0.05); whereas there was no change in the kidney
wt to body wt ratio of the right clipped kidney in this group
(R.K.W./B.W. HC1: 3.67 0.36 mglg). In contrast, the unclip-
ped kidney of these hypertensive rats was increased in its
absolute as well as its relative wt at four and nine weeks
(L.K.W. HC1: 907 130 mg; L.K.W./B,W. HC1: 4.91 0.92
mg/g, P <0.001 as compared to C1; L.K.W. HC2: 1110 121
mg, L.K.W./B.W. HC2: 3.80 1.02 mglg, P < 0.001 as
compared to C2).
In the tripletherapy treated group (HT2) there was no signif-
icant change in the relative value of the right and left kidney wt
to body wt ratio as compared to hypertensive untreated animals
(Table 3). The CE! treated group (HT1) was characterized by a
decrease in the relative wt of the right clipped kidney and an
increase in the relative wt of the left unclipped kidney as
compared to HC2 and HT2. In this group (HT,) the variance
analysis showed that the differences between the decrease in
kidney weight/body weight ratio of the clipped kidney and the
increase in that ratio in unclipped kidney was largest compared
to those values obtained in the HC2 and HT2 groups (F = 5.4,
P <0.001) (Fig. 3).
Renal renin content and immunofluorescent renal renin index
There was a general positive correlation between the im-
munofluorescent renal renin index (IRRI) and the renal renin
content (r = 0.84, F = 225, P < 0.001) (Fig. 4). The changes in
the immunofluorescent renal index in the several experimental
groups were similar quantitatively to the changes in renal renin
content.
In the sham-operated group, sacrificed at one month, the
renal renin indexes were not different between the right and the
left kidneys. At the end of the ninth week, in the sham-operated
group (C2), the renal renin indexes were still identical in both
kidneys, but significantly less that those values obtained at four
weeks (F = 10.7, P < 0.01 for RRC, and F = 27.5, P < 0.01,
for IRRI).
In contrast, in the hypertensive untreated animals, there was
a significant difference in the renal renin indexes between the
right clipped kidney and the left unclipped kidney. In compar-
ison with sham-operated rats, no decrease was observed in the
indexes of the clipped and unclipped kidneys between four and
nine weeks.
In hypertensive rats, the differences in renal renin indexes
between the two kidneys was increased by treatment (Table 2).
Tripletherapy increased by two to four times the renal renin
indexes in the clipped kidney and decreased these indexes by
50% in the unclipped kidney. Converting enzyme inhibition
increased the renal renin indexes in the contralateral unclipped
kidney to the same value as that obtained in the sham-operated
group and increased by four to ten times the renal renin indexes
of the clipped kidney.
In the three groups of animals sacrificed at nine weeks
without blockade of the renin—angiotensin system (C2, HC2,
HT2), covariance analysis revealed a general intergroup nega-
tive correlation between the renal renin indexes in the right
clipped and left unclipped kidney (renal renin content: r =
—0.43, F = 7.51, P < 0.01, line A, Fig. 5 upper panel;
immunofluorescent renal renin indexes: r =
—0.45, F = 8.64,
P < 0.01, line A, Fig. 5, lower panel). In contrast, in the
untreated hypertensive rats and in the CE! treated rats, a direct
positive correlation was shown between the renal renin indexes
of the two kidneys (renal renin content: r = 0.77, F = 32,2, P
< 0.001; immunofluorescent renal renin index: r = 0.5, F =
7.3, P < 0.02, line: b, Fig. 5).
Plasma creatinine level
Plasma creatinine levels of the three clipped groups were not
different from each other but were increased when compared
with sham-operated group (Table 3) (P < 0.05).
Histological evaluation
Vascular lesions. The most important change was fibrinoid
necrosis involving afferent arterioles, interlobar and arcuate
arteries and occasionally glomeruli. This necrosis was some-
times accompanied by perivascular cellular infiltration. These
lesions, which are characteristic of malignant hypertension,
were found in these animals despite the absence of clinical signs
of accelerated hypertension, loss of body wt and thirst. The
second type of lesion was fibrous endarteritis resulting in
"onion skin" concentric vascular thickening.
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Kidney wt, mg
Right clipped kidney
Left unclipped kidney
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Fig. 3. Histograms of clipped and unclipped kidney wi to body wE ratio
in the Jour groups ofanimoLc sacrificed at nine weeks.
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Fig. 4. Linear correlation between immunofluorescent renal renin index
and renal renin content (r = 0.84, F = 225, P < 0.00/). Logarithmic
representation.
Vascular lesions predominated in the left unclipped kidney in
the HC2 group, and tripletherapy did not prevent those lesions.
In contrast, converting enzyme inhibition completely prevented
the development of this type of lesion (P < 0.01).
Renal ischemia. The glomeruli were moderately shrunken.
Small or large cortical and/or corticomedullary zones contain-
ing atrophied tubules were seen. These tubules had narrowed
lumina and thickened walls lined by cuboidal cells. Adjacent
tubules were cystically dilated, lined by a flattened epithelium
and occasionally contained eosinophilie, hyaline casts. The
interstitium was either normal or moderately fibrotic, contain-
ing occasional inflammatory foci (Fig. 6). The extent of the
ischemic changes and of the vascular lesion as determined by
histological examination is presented in Table 3.
In the untreated hypertensive group (FTC1), examined at four
weeks, there was evidence of ischemic change in four of the
clipped kidneys and in six of the unclipped kidneys. At nine
weeks, the number of ischemic lesions between the two kidneys
was not proportional and depended on treatment (P < 0.01).
The ischemic lesions in the left unclipped kidney predominated
in the hypertensive untreated groups (N — 8 for unelipped
kidney, N = 5 for clipped kidney). In the group treated with
tripletherapy, the proportion of ischemic lesions was similar on
both sides. In contrast, lesions were predominant in the clipped
kidneys of the group treated with CEI (Pc 0,01).
At nine weeks, the percentage of ischemic lesions in the
unclipped kidneys of each group was postively correlated with
blood pressure (r = 0.81, F = 65, P < 0.001), whereas the
percentage of ischemic lesions in the clipped kidneys was
negatively correlated with blood pressure (r =
—0.69, F = 32,
P c 0.001).
Discussion
Renin—angiotensin system
The one—clip, two kidney model of experimental hyperten-
sion has been extensively investigated over the past thirty
years. Study of this model has contributed to the present
understanding of the regulation of the renin—angiotensin aldos-
terone system. Moreover, the equivalent disease, renovascular
hypertension, exists in man. For these reasons it is, in addition,
a useful model to test the efficacy as well as the benefits and the
risks of new antihypertensive drugs.
As soon as they were developed, new methods of investiga-
tion of the renin—angiotensin system were applied to the study
of this model: histological indices of coloration of the juxtaglo-
merular apparatus [2], measurement of renal renin content and
plasma renin by bioassay [11 and radioimmunoassays of angio-
tensin I and angiotensin II [22, 32]. In the study presented here,
Table 3. Evaluation of animals sacrificed at nine weeks
Untreated
Sham operated hypertension
C2,N = 13 I-1C2,N — 12
888.5 83.8
897.5 ÷ 123.2
2.78 0.21
2.80 -t 0.27
Converting enzyme
Tripletherapy inhibition
HT2,N—12 l-1T1,N=13
845.8 124.2
1110.8 121.2
2.86 ÷ 0.62
3.80 1.02
0 5
0 8
698.5 127.5
996.3 163.9
2.70 0.41
3.85 0.44
6
6
0
0
52.5 7.1
656.4 125.8
1225.1 174.2
2.34 0.48
4.34 0.44
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we have compared the results of well known methods of renin
measurement (radioimmunoassay of angiotensin I in plasma
and kidney) to new indices which offer the potential for a more
comprehensive evaluation of the renin-angiotensin system:
immunofluorescent index of renin in the juxtaglomerular appa-
ratus [33] and measurement of angiotensinogen by an enzymatic
method and by a direct radioimmunoassay [23].
The renal renin measurements have confirmed the rise in
renin content in the clipped kidney and its decrease in the
unclipped kidney, whereas the renin measurements in plasma
have confirmed the observation that, one month after clipping,
the circulating renin—angiotensin--aldosterone system was much
more stimulated than after nine weeks. However, two months
after placement of the clip unilaterally, the renin—angiotensin
system was still activated and was not normalized [32]. The
persistence of stimulation of the renin—angiotensin system was
also documented by the evolution of the renal renin content
with time. In sham-operated rats, there was a decrease in the
renal renin content between four and nine weeks, whereas this
decrease was not observed in hypertensive rats. This finding
may be the result of the unilateral clip being a more potent
stimulus of renal renin than the age of animal.
In the past, the granularity of the juxtaglomerular apparatus
was investigated by the use of glycoprotein coloration [2]. The
complete purification of mouse [30] and human renin [33] has
made it possible to make specific anti-renin antibodies. Such
antibodies have been used for the localization of renin in tissue
[33] and antibodies directed against mouse submaxillary gland
renin have been used to localize renin in the kidneys of mice,
guinea pigs [34] and rats [34, 35]: thus, the homology of renin in
different species of rodents permitted the recognition of renal
renin by these antibodies.
As previously described in renal biopsies of patients with
renal disease [33], we used an immunofluorescent renal renin
index which quantifies renin not only at the vascular pole of the
glomerulus, but also along the afferent and interlobular arteries.
The use of these antibodies permitted the establishment of a
semi-quantitative immunofluorescent method to define the state
of hyperplasia of the juxtaglomerular apparatus under several
experimental conditions. It closely correlated to the measure-
ment of the enzymatic activity of renal renin extract. Both
methods of investigation have documented the similarity of the
intrarenal renin in both kidneys at four weeks and again at nine
weeks in the sham-operated group. In contrast, in the hyper-
tensive untreated groups, the renal renin indexes reflected the
rise of renin in the clipped kidney and its decrease in the
contralateral kidney. These abnormalities were more marked,
by comparison with sham-operated rats, at nine weeks than at
four weeks. Interestingly Cantin et a! [35], using mouse renin
antiserum in another model of renovascular hypertension in
rats, also reported that in the ischemic kidneys there was no
significant increase in the intensity of immunostaining, but there
was, however, a significant increase in the number of juxtaglo-
merular apparatuses, preglomerular and interlobular arteries
stained by the renin antiserum. We did not find any significant
correlation between plasma renin concentration and the renal
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I 20 40 60 80 100 Fig. 6. Section of ischemic kidney showing the three lesions of ische-
mia: tubular dilation, inflammatory and fibrotic infiltration and
shrunken of glomeruli (x 76).
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Fig. S. Schematic representation of covariance analysis of renal renin
indices (immunofluorescent renal renin index and renal renin content)
in both clipped and unclipped kidneys in the four groups of animals
sacrificed at nine weeks. Line A, general negative correlation between
renal renin indices in the two kidneys of animals not receiving convert-
ing enzyme inhibitor. Line B, positive correlation between renal renin
indices in the two kidneys in the group of hypertensive untreated and
hypertensive animals treated with converting enzyme inhibition.
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renin indices. It is likely due to the fact that both methods of
investigation do not measure exactly the same biological
events. Plasma renin concentration is an index of active renin
release, whereas measurements of renin content and im-
munofluorescence of the juxtaglomerular apparatus investigate
renin biosynthesis and storage within the kidney.
As with the purification of renin, the purification of rat
angiotensinogen has made it possible to develop specific anti-
angiotensinogen antibodies (23]. These antibodies recognize
renin substrate as well as its residue, des-angio 1-angiotensin-
ogen, which explains why higher values are obtained in plasma
by the direct radioimmunoassay of antiogensinogen than by the
enzymatic assay, which detects only active angiotensinogen. In
a study of sodium depletion, converting enzyme inhibition, and
adrenal insufficiency, Clauser et al [24] observed that the
difference in estimates of angiotensinogen by both assays is
directly proportional to the level of circulating renin. In this
report, we extended this observation to the one—clip, two
kidney model of renal hypertension in rats, which was charac-
terized by a decreased amount of active angiotensinogen and a
concomitant rise in plasma renin, whereas there was no signif-
icant change in total immunoreactive angiotensinogen.
These data demonstrate that, throughout its entire course,
this model of experimental hypertension is characterized by
stimulation of the renin—angiotensin system. Therefore, it is not
surprising that blood pressure is more easily controlled by a
compound which blocks the renin—angiotensin system through
inhibition of converting enzyme than by other antihypertensive
drugs [361.
We have analyzed the consequences of two different thera-
peutic approaches on the renin—angiotensin system and on the
histological characteristics of the kidneys. The first therapeutic
approach was to use conventional antihypertensive agents. The
hypertensive rats were initially treated by dihydralazine (3
mg/kg twice a day), a dose which was proven to be very
affecting in SHR rats [37]. The failure of their treatment to
control BP made it necessary to double the dose, and then to
add successively clonidine and furosemide within 15 days.
Even when these three drugs were used, at a dose where they
were pharmacologically active, they were unable to normalize
BP. Their use was accompanied by a reenforcement of the
activity of the renin—angiotensin system as shown by a higher
plasma renin level, a lower plasma angiotensinogen concentra-
tion, a higher renal renin content and a higher immunofluores-
cent renal renin index in the clipped kidney. The differences
between the renal renin indexes in the clipped and unclipped
kidneys were increased in this tripletherapy group. The second-
ary stimulation of the renin—angiotensin system induced by the
vasodilator and the diuretic and the increase in plasma volume
observed during tripletherapy despite furosemide administra-
tion can explain the resistance to treatment. Both abnormalities
are absent during converting enzyme inhibition.
This second therapeutic approach exhibited different effects
in this model of experimental hypertension. It was very effec-
tive in normalizing BP and was able to decrease plasma
aldosterone. The suppression of angiotensin II generation most
likely occurred consequent to blockade of converting enzyme
activity. Several effects on the circulating and intrarenal
renin—angiotensin system support the contention that angioten-
sin II levels were reduced. Thus, plasma renin level was
increased by four times in comparison with untreated hyperten-
sive rats. Plasma angiotensinogen was lowered and probably an
increased amount of des-angio 1-angiotensinogen was present in
plasma, as it was observed in normotensive rats treated with
CEI [24]. The biosynthesis of renin was stimulated in both
kidneys since the renal renin content and the immunofluores-
cent renin index was increased in the clipped kidney and also in
the unclipped kidney.
The increased renin biosynthesis and release of the clipped
kidney can decrease renin biosynthesis in the contralateral
kidney, through the negative feedback effect of angiotensin II
[38]. In the tripletherapy group, sodium depletion, stimulation
of the sympathetic nervous system, and decrease in the perfu-
sion pressure increased renin biosynthesis and release by the
clipped kidney. Therefore angiotensin II exerted a potent effect
in the unclipped kidney and its renin indexes decreased. In the
CE! group where angiotensin II formation was prevented, the
stimulation of renin release and biosynthesis by the major fall in
perfusion pressure and the lack of angiotensin I! explain the rise
in renin content of the clipped kidneys. Instead of being
accompanied by a further fall of the renin content in the
unclipped kidney as in the tripletherapy group, it was accom-
panied by a rise in renin content, mainly dependent on the
angiotensin II formation blockade.
Kidney mass and hislopaihology
In hypertensive rats, there was no evidence of a decrease in
wt of the clipped kidney in the absence of antihypertensive
treatment. The predominant effect of clipping one renal artery
on kidney mass was the hypertrophy of the contralateral
kidney. Hypertension in these untreated animals was charac-
terized by several lesions. Lesions of renal ischemia were
observed in both kidneys, whereas vascular lesions were pre-
sent only in the unclipped kidney, which is exposed to the
increased perfusion pressure.
Tripletherapy had no influence on these lesions. In contrast,
converting enzyme inhibition is accompanied by a disappear-
ance of the vascular lesions in the unclipped kidney, which is
certainly the consequence of the normalization of BP. On the
other hand, however, in the clipped kidney, converting enzyme
inhibition was accompanied by an accentuation of the charac-
teristic lesions of renal ischemia, which is not observed with
tripletherapy. These histological changes, improvement of the
unclipped kidney, and alterations of the clipped kidney are
likely to be associated with the functional changes induced by
CE! in this model. Huang et a! [39] reported an acute beneficial
effect of CEI on glomerular filtration rate, diuresis and natri-
uresis in the contralateral unclipped kidney and a harmful effect
on the same parameters in the clipped kidney. In their study,
renal functional effects of CE! were attributed to the decrease in
blood pressure in the clipped kidney and to the decrease in
circulating angiotensin II in the unclipped kidney. It has also
been observed during captopril treatment of one—clip, one
kidney hypertensive rats that the fall in blood pressure could
induce death, quite probably related to renal insufficiency [19],
and that plasma urea and creatinine concentrations in plasma
increased during the fall in blood pressure induced by captopril
in two—clip, two—kidney hypertensive rats, whereas such a
deterioration in renal function was not observed after
hydralazine [20]. Helmchen [201 has shown, in a four day study,
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that tubular lesions were more severe in the clipped kidney of
animals treated with inhibitors of the renin angiotensin system
than in those treated with vasodilators, although an identical
decrease in BP was observed with both treatments.
The rise of systemic BP, the predominant vasoconstrictor
effect of angiotensin II on the efferent arteriole to maintain
glomerular filtration rate [40], and the redistribution of renal
blood flow to the deep juxtamedullary nephrons with an in-
crease in their renin content [411 are the compensatory extra
and intrarenal effects of the activation of the renin—angiotensin
system in the stenotic kidney during a renal artery stenosis. Our
histological observations suggest a long term harmful effect on
the stenotic kidney of the supression of this activation and of
the normalization of BP by administration of a converting
enzyme inhibitor. It is not possible at this time to atttribute the
observed lesions in the clipped kidney to the functional change
induced by the decrease in perfusion pressure, or to the
inhibition of the plasma and renal renin—angiotensin system.
The results obtained with CE! cannot be compared to those
obtained with tripletherapy, which did not succeed to normalize
blood pressure. Independent of their pathophysiological mech-
anisms, these observations might have important clinical impli-
cations. Although antihypertensive therapy in this experimental
model of hypertension and, in particular, inhibition of convert-
ing enzyme, appeared to have a protective effect on the
unclipped kidney, the degree of ischemic damage in the clipped
kidney was increased. This suggests that renal revasculariza-
tion by surgery or endoluminal dilatation are necessary proce-
dures for the long term treatment of renovascular hypertension
in man, rather than merely using normalization of BP as the
end—point of therapy.
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